Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Defending Your Life: Sharer and Perlmutter On Amgen’s R&D Strategy

Executive Summary

Since joining Amgen in 2000 and 2001, respectively, CEO Kevin Sharer and Exec VP-R&D Roger Perlmutter, have been the frontmen for the firm's aggressive approach to drug research and development - which has had some spectacular results. During the Aug. 15 call detailing the restructuring plan to analysts, the duo was asked about Amgen's ramp-up of R&D in 2006 and generally about R&D productivity. Their answers provide perspective on the feeling surrounding the need to cut back on the area where Amgen has taken such a lead in the industry, on the unique difficulties of being a biotech giant, and on Amgen's performance compared to its closest competitor - Genentech.

You may also be interested in...



Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization

As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program - including scaling back from its industry-leading approach of investing a high percentage of sales on R&D

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel